Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSN222 in advanced solid tumors or lymphoma
NCT05842785Phase 2Recruiting
- Sponsor
- Tyligand Bioscience
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TSN222 in solid tumor, lymphoma, head and neck squamous cell carcinoma (HNSCC), melanoma, sponsored by Tyligand Bioscience. Started Jul 2023; status: recruiting.
02
Drugs
TSN222
03
Conditions
solid tumorlymphomahead and neck squamous cell carcinoma (HNSCC)melanoma
Beyond the preview
Go deeper on NCT05842785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05842785.